Insulin Aspart Research: What 1,515 Studies Show (2026) | RetatrutideCompare

Insulin Aspart — 1,515 studies indexed on PubMed. Rapid-acting prandial insulin analog. Half-life: ~1 hour. FDA status: FDA-approved (2000).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Insulin Aspart?

There are approximately 1,515 studies indexed on PubMed that mention Insulin Aspart (NovoLog, Fiasp), based on a search last updated 2026-06-18.

Is Insulin Aspart FDA-approved?

FDA status: FDA-approved (2000).

How does Insulin Aspart work?

Rapid-acting prandial insulin analog.

Reference facts

Also known as: NovoLog, Fiasp
Category: Hormonal & Pituitary
Mechanism of action: Rapid-acting prandial insulin analog.
Targets: Insulin receptor
Indications under research or approved: Diabetes — prandial insulin
Regulatory status (reference entry): FDA-approved (2000)
Half-life: ~1 hour
Sequence: GIVEQCCTSICSLYQLENYCN
Sequence notes: Rapid-acting insulin: B-chain Pro28 → Asp, reducing dimerization.
Molecular weight (Da): 5826
PDB accession: 1ZEH
Originator / sponsor: Novo Nordisk
First reported: 1994

Primary References

NovoLog FDA label

Explore research articles about Insulin Aspart

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.